Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.38 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24363272 | 0.84 | GNPAT (0.48) | FOLH1ALBNPY1R | |
| SCHEMBL26440808 | 0.82 | FOLH1 (0.42) | FOLH1ALBNPY1RNPY2RNPY4R | |
| SCHEMBL29569172 | 0.82 | QRFPR (0.46) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3961412 | 0.82 | QRFPR (0.46) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL3961387 | 0.82 | QRFPR (0.46) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30193290 | 0.81 | QRFPR (0.45) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL16554268 | 0.81 | NPY4R (0.41) | NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL38666189 | 0.81 | CCKBR (0.48) | FOLH1NMUR2NMUR1NPY1RNPY4R | |
| SCHEMBL17246772 | 0.78 | FOLH1 (0.51) | FOLH1ALB | |
| SCHEMBL29435094 | 0.78 | SLC15A2 (0.45) | FOLH1NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919579-B2 | Imaging and therapeutic targeting of prostate and bladder tissues | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090123381-A1 | IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES | US ARMY, SECRETARY OF THE ARMY | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123381-A1 | IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES | ADM2, DAB2IP, ARG2 | FOLH1 15/4885ALB 4378/4885NMUR2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.